logo
Twitter
Discord
Email
logo
Haemonetics Corporation

Haemonetics Corporation

NYSE•HAE
CEO: Mr. Christopher A. Simon
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1991-05-10
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Contact Information
125 Summer Street, Boston, MA, 02110, United States
781-848-7100
www.haemonetics.com
Market Cap
$4.07B
P/E (TTM)
23.6
27.1
Dividend Yield
--
52W High
$87.32
52W Low
$47.32
52W Range
90%
Rank29Top 12.7%
5.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q2 2026 Data

Revenue

$327.32M-5.27%
4-Quarter Trend

EPS

$0.81+22.73%
4-Quarter Trend

FCF

$106.31M+169.88%
4-Quarter Trend

2026 Q2 Earnings Highlights

Key Highlights

Operating Income Jumps 22.9% Operating income reached $112.36M for six months, increasing 22.9% driven by pricing and lower restructuring costs.
Gross Margin Expands Significantly Gross margin improved to 59.7% from 53.2% year-over-year, reflecting strong pricing benefits across units.
Operating Cash Flow Surges Cash provided by operations totaled $128.72M, a massive increase from $21.40M last year period.
Net Income Shows Slight Growth Net income grew slightly 0.7% to $72.72M for six months, while basic EPS rose 7.0% to $1.52.

Risk Factors

Revenue Declines 4.8% Total net revenues fell 4.8% to $648.71M, driven by Plasma transition and Whole Blood divestiture impacts.
Intangible Impairment Rises Intangible asset impairment charges increased significantly to $8.58M this period, up from $2.39M previously.
Plasma Revenue Drops Plasma net revenues decreased 7.0% to $255.26M due to North America customer transition impacts.
Contingent Consideration Liability Contingent consideration liability stands at $2.09M, based on Level 3 unobservable inputs and future performance milestones.

Outlook

New Share Repurchase Program Board approved a new $500.0M share repurchase program through April 2028 to offset dilution impact.
Market Alignment Initiative New strategic initiative launched in May 2025 focuses on cost reduction and directing resources for growth.
2026 Notes Maturity Imminent $300.0M principal balance of 2026 Notes matures March 1, 2026; holders can convert until September 2025.
Strategic Investment Focus Company holds $73.7M investment in Vivasure Medical, expanding Hospital business unit portfolio strategically.

Peer Comparison

Revenue (TTM)

Bausch Health Companies Inc.BHC
$8.26B
-12.7%
DENTSPLY SIRONA Inc.XRAY
$3.62B
-7.1%
Acadia Healthcare Company, Inc.ACHC
$3.27B
+4.6%

Gross Margin (Latest Quarter)

Bausch Health Companies Inc.BHC
173.2%
+101.0pp
Acadia Healthcare Company, Inc.ACHC
96.7%
+72.8pp
QuidelOrtho CorporationQDEL
93.2%
+44.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
HAE$4.07B23.619.4%50.1%
CPRX$2.90B13.326.4%0.2%
BHC$2.56B7.1-38.2%78.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.1%
Flat Growth
4Q Net Income CAGR
1.0%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 5, 2026
|
EPS:$1.27
|
Revenue:$331.90M
Reports
All Years
  • Form 10-Q - Q2 2026

    Period End: Sep 27, 2025|Filed: Nov 6, 2025|
    Revenue: $327.32M-5.3%
    |
    EPS: $0.81+22.7%
    Miss
  • Form 10-Q - Q1 2026

    Period End: Jun 28, 2025|Filed: Aug 7, 2025|
    Revenue: $321.39M-4.4%
    |
    EPS: $0.71-5.3%
    Miss
  • Form 10-K - FY 2025

    Period End: Mar 29, 2025|Filed: May 21, 2025|
    Revenue: $1.36B+4.0%
    |
    EPS: $3.31+42.7%
    Beat
  • Form 10-Q - Q3 2025

    Period End: Dec 28, 2024|Filed: Feb 6, 2025|
    Revenue: $348.54M+3.7%
    |
    EPS: $0.75+21.0%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Sep 28, 2024|Filed: Nov 7, 2024|
    Revenue: $345.51M+8.6%
    |
    EPS: $0.66+34.7%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Jun 29, 2024|Filed: Aug 8, 2024|
    Revenue: $336.17M+8.0%
    |
    EPS: $0.75-7.4%
    Miss
  • Form 10-K - FY 2024

    Period End: Mar 30, 2024|Filed: May 20, 2024|
    Revenue: $1.31B+12.0%
    |
    EPS: $2.32+2.2%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Dec 30, 2023|Filed: Feb 8, 2024|
    Revenue: $336.25M+10.1%
    |
    EPS: $0.62-4.6%
    Miss